Zevra Therapeutics, Inc. Payments to Acquire Marketable Securities
Zevra Therapeutics, Inc. (ZVRA) reported Payments to Acquire Marketable Securities of $14.67 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2016-05-13
- Zevra Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2016-03-31 was $14.67M.
- Zevra Therapeutics, Inc. payments to acquire marketable securities for fiscal 2015 was $19.00M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|
| 2016-03-31 | $14.67M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $19.00M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |